The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 14, 2017

Filed:

Jun. 21, 2013
Applicant:

Seqirus Uk Limited, Berkshire, GB;

Inventors:

Audino Podda, Sovicille, IT;

Nicola Groth, Buonconvento, IT;

Michele Pellegrini, Castelnuovo Berardenga, IT;

Assignee:

Seqirus UK Limited, Berkshire, GB;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 39/145 (2006.01); A61K 39/12 (2006.01); A61K 39/00 (2006.01); A61K 39/39 (2006.01);
U.S. Cl.
CPC ...
A61K 39/145 (2013.01); A61K 39/12 (2013.01); A61K 39/39 (2013.01); A61K 2039/545 (2013.01); A61K 2039/55 (2013.01); A61K 2039/55566 (2013.01); A61K 2039/58 (2013.01); A61K 2039/70 (2013.01); C12N 2760/16134 (2013.01); C12N 2760/16234 (2013.01);
Abstract

An influenza vaccine adjuvanted with a sub-micron oil-in-water emulsion elicits significantly higher immune responses in human pediatric populations. Compared to an existing unadjuvanted pediatric influenza vaccine, the adjuvanted vaccines provided herein can induce in children a longer persistence of high serum antibody titers and also longer seroconversion and seroprotection. The improvement in immune responses is seen for both influenza A virus and influenza B virus strains, but it is particularly marked for influenza B virus. Moreover, while the existing vaccine provides poor immunity in children after a single dose, the adjuvanted vaccine provides high seroprotection rates against the influenza A virus H3N2 subtype even after a single dose. Furthermore, the adjuvanted vaccine offers significantly better seroprotection against mismatched strains of influenza A virus.


Find Patent Forward Citations

Loading…